Featured Research

from universities, journals, and other organizations

New Drug Reduces Disease Activity In Multiple Sclerosis, Investigation Suggests

Date:
May 7, 2007
Source:
American Academy of Neurology
Summary:
A new drug under investigation shows a reduction in disease activity in multiple sclerosis, according to two recent studies. The drug reduced disease activity as indicated by MRI scans.

A new drug under investigation shows a reduction in disease activity in multiple sclerosis (MS), according to two studies. The drug reduced disease activity as indicated by MRI scans.

Related Articles


Both of the studies involved people with the relapsing-remitting form of MS, where symptoms flare up and then subside. By 24 weeks, treatment with the drug rituximab reduced the number of areas of brain damage, or lesions, in people with MS and the number of relapses, or times when symptoms flare up, when compared with placebo.

Rituximab is a therapeutic antibody that selectively targets and depletes a subset of immune cells called B-cells by targeting a specific protein on their surface.

"This is the first drug to target B-cells and may represent a potential new treatment strategy for relapsing-remitting MS," said study author Stephen Hauser, MD, of the University of California, San Francisco, and a member of the American Academy of Neurology. "While these are early stage clinical trials, these results are exciting, because the current drugs available for MS are only partially effective in reducing disease activity and preventing exacerbations. New and more effective treatments for MS are sorely needed, especially for people who do not adequately respond to currently available medications. These data are also important because they demonstrate that B-cells, which are the precursors of antibody-producing cells, play an essential role in mediating relapses of MS."

In the first study, a randomized, placebo-controlled trial, 69 people were given two infusions of rituximab two weeks apart and 35 were given a placebo. The participants were followed for six months. Those given rituximab had approximately 90 percent fewer brain lesions than those given placebo. During the six-month period, 58 percent fewer of those taking the drug had relapses than those taking placebo; 14.5 percent of the rituximab patients experienced at least one relapse during the six-month period, compared to 34.3 percent of the patients receiving a placebo.

"Treatment with rituximab was generally safe and well-tolerated in the study," Hauser said. With the exception of infusion-associated adverse events, the rates of adverse events and serious adverse events were comparable between those taking rituximab and those taking placebo. Although there were more first infusion-associated adverse events with rituximab, the majority of adverse events resolved with appropriate medical treatment. The overall rates of infection were also comparable with rituximab and placebo.

In the second study, an uncontrolled open label trial, 26 people received two infusions of rituximab two weeks apart (one course of treatment) and then another treatment course six months later. Patients were followed for a total of at least one year. Though a placebo group was not included in this safety study, brain lesions were reduced by more than 90 percent and the relapse rate was reduced from an average of at least one per patient per year to only a few for the entire group over the year of treatment. Side effects were limited to mild to moderate reactions to the drug infusion, according to study author Amit Bar-Or, MD, of the Montreal Neurological Institute at McGill University in Montreal, Canada, and a member of the American Academy of Neurology.

Both studies were supported by Genentech, Inc., and Biogen Idec., the companies marketing the drug in the United States. The drug is currently approved for use with certain types of lymphoma and for a moderate to severe form of rheumatoid arthritis; it is not approved for use in multiple sclerosis.

Rituximab has been associated with fatal infusion reactions, tumor lysis syndrome, progressive multifocal leukoencephalopathy, renal toxicity, and other adverse effects.

The findings were presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 -- May 5, 2007.


Story Source:

The above story is based on materials provided by American Academy of Neurology. Note: Materials may be edited for content and length.


Cite This Page:

American Academy of Neurology. "New Drug Reduces Disease Activity In Multiple Sclerosis, Investigation Suggests." ScienceDaily. ScienceDaily, 7 May 2007. <www.sciencedaily.com/releases/2007/05/070501142331.htm>.
American Academy of Neurology. (2007, May 7). New Drug Reduces Disease Activity In Multiple Sclerosis, Investigation Suggests. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2007/05/070501142331.htm
American Academy of Neurology. "New Drug Reduces Disease Activity In Multiple Sclerosis, Investigation Suggests." ScienceDaily. www.sciencedaily.com/releases/2007/05/070501142331.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Winter Can Cause Depression — Here's How To Combat It

Winter Can Cause Depression — Here's How To Combat It

Newsy (Nov. 23, 2014) Millions of American suffer from seasonal depression every year. It can lead to adverse health effects, but there are ways to ease symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com
WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins